Mauritius Healthcare Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Mauritius Healthcare Daily.

March 2026

Mo	Tu	We	Th	Fr	Sa	Su
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

April 2026

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30

May 2026

Mo	Tu	We	Th	Fr	Sa	Su
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

Press releases published on April 21, 2026

Apr. 21, 2026

Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting

GlobeNewswire

Apr. 21, 2026

Becoming Independent Named No. 17 on “The NonProfit Times' 2026 Best Nonprofits To Work For”

GlobeNewswire

Apr. 21, 2026

Record-Breaking SpringFest 2026 Affirms A4M as the Central Forum for Longevity Medicine

GlobeNewswire

Apr. 21, 2026

Remix Therapeutics Announces Oral Presentation of First-in-Class Small Molecule MYB mRNA Degrader REM-422 Phase 1/2 ARIA Trial Results at the 2026 American Society of Clinical Oncology Annual Meeting

GlobeNewswire

Apr. 21, 2026

Xeltis releases groundbreaking new 12-month EU pivotal data for aXess™ demonstrating the transformative potential in hemodialysis treatment

GlobeNewswire

Apr. 21, 2026

Trethera Announces Appointment of M. Andrew (“Drew”) Woodmansee to Board of Directors

GlobeNewswire

Apr. 21, 2026

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting

GlobeNewswire

Apr. 21, 2026

ITM to Announce Quality of Life Data from the Phase 3 COMPETE Trial in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) at ASCO 2026

GlobeNewswire

Apr. 21, 2026

GLP Diet App Launches Personalized Wellness App for GLP-1 Medication Users, Earns 2,500+ App Reviews

GlobeNewswire

Apr. 21, 2026

Global Virus Network on Measles Resurgence

GlobeNewswire

Apr. 21, 2026

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

GlobeNewswire

Apr. 21, 2026

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

GlobeNewswire

Apr. 21, 2026

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

GlobeNewswire

Apr. 21, 2026

NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

GlobeNewswire

Apr. 21, 2026

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

GlobeNewswire

Apr. 21, 2026

4BIO Capital portfolio company Ray Therapeutics announces upsized and oversubscribed $125 Million Series B financing for vision restoration treatments

GlobeNewswire

Apr. 21, 2026

ImPact Biotech Announces Upcoming Data Presentations for Padeliporfin VTP at AUA and ASCO 2026

GlobeNewswire

Apr. 21, 2026

Concerned About Supporting Erectile Health? Life Extension Launches New Men’s Sexual Health Supplement

GlobeNewswire

Apr. 21, 2026

Dewpoint Therapeutics Reports Preclinical Data on Oral MYC Condensate Modulator at AACR 2026

GlobeNewswire

Apr. 21, 2026

Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026

GlobeNewswire